




Supplementary Fig. S1. The distribution and comparison of inflammatory biomarkers.

A: Comparison of inflammatory biomarkers between patients with and without complications; **B:** Comparison of inflammatory biomarkers in the IST group between patients with and without complications.

Supplementary Table S1. The diagnostic efficacy of different inflammatory biomarkers and prediction models.

Inflammatory biomarkers	Cut-off point	Sensitivity	Specificity	AUC	95%Confidential Interval
PLR	95.618	90.48%	41.38%	0.673	0.523-0.823
NLR	2.045	80.95%	48.28%	0.640	0.484-0.797
MPV(fL)	9.385	28.57%	93.1%	0.592	0.425-0.759
RF(IU/mL)	9.5	66.67%	88.89%	0.748	0.591-0.904
ESR(mm/h)	56.5	33.33%	96.43%	0.657	0.497-0.816
CRP(mg/L)	3.2	85.71%	57.69%	0.730	0.582-0.878
Pre-1	-	-	-	0.489	0.423-0.556
Pre-2	-	-	-	0.746	0.634-0.857
Pre-3	-	100%	34.48%	0.672	0.584-0.760
Pre-4	-	90.48%	79.31%	0.849	0.750-0.948
Pre-5	-	76.19%	93.1%	0.847	0.742-0.951
Pre-6	-	33.33%	96.55%	0.649	0.541-0.758

AUC: Area under curve; Pre-1: The clinical prediction model based on at least 1 positive biomarkers; Pre-2: The clinical prediction model based on at least 2 positive biomarkers; Pre-3: The clinical prediction model based on at least 3 positive biomarkers; Pre-4: The clinical prediction model based on at least 4 positive biomarkers; Pre-5: The clinical prediction model based on at least 5 positive biomarkers; Pre-6: The clinical prediction model based on at least 6 positive biomarkers.

Supplementary Table S2. Univariate and multivariate Cox regression of inflammatory biomarkers group.

Variable	Univariate analysis			Multivariate analysis		
	Hazard ratio (HR)	95%CI	p-value	HR	95%CI	p-value
ESR group	3.044	1.225, 7.565	0.017	2.552	0.975, 6.680	0.056
RF group	5.058	2.027, 12.621	<0.001	3.829	1.495, 9.803	0.005
CRP group	4.838	1.423, 16.445	0.012	3.259	0.904, 11.753	0.071
PLR group	4.498	1.045, 19.358	0.043			
NLR group	3.201	1.074, 9.544	0.037	3.334	1.069, 10.339	0.038
MPV group	3.269	1.254, 8.521	0.015			

The inflammatory biomarkers are grouped by cut-off points.

Supplementary Table S3. The pre-operative immunosuppressive regimen of all patients.

Patients	Age/Sex	Immunosuppressive regimen
1	53/F	Thalidomide 50mg qd, Methylprednisolone 4mg qd
2	21/F	Methylprednisolone 8mg qd, Hydroxychloroquine 200mg bid, Ciclosporin 50mg qd
3	48/M	Methylprednisolone 8mg qd
4	54/M	Prednisone 50mg qd, Hydroxychloroquine 200mg bid,
5	30/M	Methylprednisolone 8mg qd
6	37/M	Methylprednisolone 40mg qd, Hydroxychloroquine 50mg qd
7	37/M	Prednisone 10mg qd
8	37/F	Mycophenolate mofetil 750mg bid, Prednisone 10mg qd
9	44/M	Prednisone 10mg qd
10	24/F	Methylprednisolone 36mg qd, Hydroxychloroquine 200mg bid
11	41/F	Prednisone 30mg qd, Hydroxychloroquine 30mg qd, Methotrexate 10mg qw
12	40/F	Hydroxychloroquine 200mg qd, Prednisone 5mg qd
13	45/F	Prednisone 10mg qd
14	35/M	Prednisone 10mg qd, Thalidomide 50mg qd
15	32/F	Prednisone 5mg qd, Thalidomide 100mg qd
16	51/M	Methylprednisolone 40mg qd
17	35/M	Methylprednisolone 40mg qd, Cyclophosphamide 100mg qd
18	52/F	Prednisone 15mg qd, Cyclophosphamide 200mg qod
19	31/M	Methylprednisolone 12mg qd, Thalidomide 50mg qd
20	30/M	Adalimumab 40mg q2w; After admission:Prednisone 5mg qd
21	46/M	Methylprednisolone 4mg qd, Cyclophosphamide 100mg qod
22	40/M	Prednisone 50mg qd, Mycophenolate mofetil 750mg bid
23	30/M	Prednisone 5mg qd, Hydroxychloroquine 200mg qd
24	40/M	Prednisone 5mg qd, Methotrexate 10mg qw
25	44/F	Prednisone 5mg qd, Mycophenolate mofetil 500mg bid
26	32/M	Methylprednisolone 4mg qd, Cyclophosphamide 100mg qod, Adalimumab 40mg q2w; After admission:Methylprednisolone 4mg qd.
27	52/M	Methylprednisolone 8mg qd, Mycophenolate mofetil 750mg bid
28	32/F	Prednisone 15mg qd, Thalidomide 50mg qd, Adalimumab 40mg q2w; after admission: Prednisone 15mg qd.
29	35/M	Methylprednisolone 8mg qd
30	30/M	Methylprednisolone 10mg qd
31	39/F	Prednisone 5mg qd, Mycophenolate mofetil 750mg bid, Adalimumab 40mg q2w; after admission: Prednisone 5mg qd.
32	45/F	Prednisone 7.5mg qd, Adalimumab 40mg q2w; after admission: Prednisone 7.5mg qd.
33	38/M	Methylprednisolone 12mg qd, Thalidomide 50mg qd, Cyclophosphamide 800mg qm; after admission: Methylprednisolone 12mg qd.